NRx Pharmaceuticals’ (NRXP) “Buy” Rating Reiterated at BTIG Research

by · The Cerbat Gem

BTIG Research reissued their buy rating on shares of NRx Pharmaceuticals (NASDAQ:NRXP – Free Report) in a research note issued to investors on Monday morning,Benzinga reports. BTIG Research currently has a $10.00 price objective on the stock.

NRXP has been the subject of several other reports. HC Wainwright reissued a “buy” rating on shares of NRx Pharmaceuticals in a research report on Tuesday, August 25th. Wall Street Zen downgraded shares of NRx Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Zacks Research lowered shares of NRx Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Wednesday, August 26th. UBS Group reissued a “buy” rating on shares of NRx Pharmaceuticals in a research report on Wednesday, August 26th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of NRx Pharmaceuticals in a research note on Wednesday, August 5th. Five equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $34.50.

Read Our Latest Stock Report on NRx Pharmaceuticals

NRx Pharmaceuticals Stock Performance

NASDAQ NRXP opened at $3.35 on Monday. The company has a market cap of $145.06 million, a PE ratio of -6.09 and a beta of 2.19. NRx Pharmaceuticals has a 52-week low of $1.62 and a 52-week high of $5.05. The firm’s 50 day moving average price is $3.60 and its 200-day moving average price is $3.21.

NRx Pharmaceuticals (NASDAQ:NRXP – Get Free Report) last announced its quarterly earnings results on Friday, August 14th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.33). The firm had revenue of $1.10 million during the quarter, compared to analyst estimates of $1.33 million. On average, analysts forecast that NRx Pharmaceuticals will post -0.36 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in NRXP. Ethos Financial Group LLC grew its stake in NRx Pharmaceuticals by 33.6% in the 1st quarter. Ethos Financial Group LLC now owns 15,900 shares of the company’s stock valued at $34,000 after acquiring an additional 4,000 shares during the period. Squarepoint Ops LLC acquired a new stake in NRx Pharmaceuticals in the 2nd quarter worth about $54,000. Global Retirement Partners LLC purchased a new position in NRx Pharmaceuticals in the 4th quarter valued at $107,000. Bleakley Financial Group LLC purchased a new stake in NRx Pharmaceuticals during the 4th quarter valued at about $318,000. Finally, AdvisorShares Investments LLC raised its holdings in NRx Pharmaceuticals by 28.2% in the 1st quarter. AdvisorShares Investments LLC now owns 420,467 shares of the company’s stock valued at $896,000 after acquiring an additional 92,463 shares during the last quarter. 4.27% of the stock is owned by institutional investors and hedge funds.

About NRx Pharmaceuticals

(Get Free Report)

NRx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders, particularly conditions involving mood disorders, suicidality and post-traumatic stress disorder. The company’s programs are designed to address significant unmet medical needs in psychiatric and neurological care.

NRx Pharmaceuticals’ lead investigational product is NRX-101, an oral fixed-dose combination of D-cycloserine and lurasidone being developed for bipolar depression with acute suicidal ideation or behavior.

See Also